Cancer Genotyping Assays: Somatic & Germline
Cancer genotyping can be used to identify a predetermined genetic aberration, such as somatic mutations, copy number variations, gene expression changes, and/or DNA methylation.
Cancer Genotyping of Specific Genes or Variants
Somatic Mutation Detection
TaqMan® Mutation Detection Technology—Offering Superior Sensitivity for Your Cancer Biomarker Research
TaqMan® Mutation Detection Assays detect somatic mutations in genes that are associated with cancer. These research use only assays are powered by competitive allele-specific TaqMan® PCR technology, also known as castPCR™ technology. The castPCR™ technology is highly specific and sensitive, and it can detect rare amounts of mutated DNA in a sample that contains large amounts of normal, wild type DNA. These assays are compatible with different sample types, such as cell lines, FFPE tissue samples, and fresh frozen tissue samples.
- High specificity—mutant allele detection is based on an allele-specific primer, while the wild-type background is suppressed by an MGB blocker oligonucleotide
- High sensitivity—assays can detect as low as 0.1% mutant molecules in a background of wild type gDNA as demonstrated in spiking experiments
- Wide dynamic range and excellent PCR efficiency—assays demonstrate at least 4 logs of dynamic range and an average efficiency of 100 ± 10%
- Fast, simple workflow—like other TaqMan® Assays, typically requires 3 hours from sample to results, with minimum hands-on time
- Our current assay set covers 285 assays to key mutation targets in 23 cancer genes
Learn more about TaqMan® Mutation Detection Assays powered by castPCR™ Technology
Application note: Accurate and sensitive mutation detection